Suchen
Vertex Pharmaceuticals Inc
VRTXZur Watchlist hinzufügen
528.900USD
-17.220-3.15%
Handelsschluss 09-08 16:00（ET）
134.04BMarktkapitalisierung
31.11KGV TTM
mehr Informationen über Vertex Pharmaceuticals Inc Unternehmen
Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).
Vertex Pharmaceuticals Inc Profil
BörsenkürzelVRTX
Name des UnternehmensVertex Pharmaceuticals Inc
IPO-datumJul 24, 1991
CEOKewalramani (Reshma)
Anzahl der mitarbeiter6100
WertpapierartOrdinary Share
GeschäftsjahresendeJul 24
Addresse50 Northern Avenue
StadtBOSTON
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl02210
Telefon16173416393
Websitehttps://www.vrtx.com/
BörsenkürzelVRTX
IPO-datumJul 24, 1991
CEOKewalramani (Reshma)
Führungskräfte von Vertex Pharmaceuticals Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Reshma Kewalramani, M.D.
Dr. Reshma Kewalramani, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
47.80K
+28.61%
Mr. Bruce I. Sachs
Mr. Bruce I. Sachs
Lead Independent Director
Lead Independent Director
39.00K
-15.38%
Dr. Ourania (Nia) Tatsis, Ph.D.
Dr. Ourania (Nia) Tatsis, Ph.D.
Executive Vice President, Chief Regulatory and Quality Officer
Executive Vice President, Chief Regulatory and Quality Officer
36.25K
+18.62%
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
35.24K
--
Ms. Joy Liu
Ms. Joy Liu
Corporate Secretary
Corporate Secretary
19.07K
-4.34%
Mr. Jonathan Biller, J.D.
Mr. Jonathan Biller, J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
13.66K
-78.45%
Dr. Sangeeta N. Bhatia, M.D., Ph.D.
Dr. Sangeeta N. Bhatia, M.D., Ph.D.
Independent Director
Independent Director
4.92K
+12.69%
Ms. Diana L. McKenzie
Ms. Diana L. McKenzie
Independent Director
Independent Director
2.58K
+5.69%
Ms. Jennifer J. Schneider, M.D.
Ms. Jennifer J. Schneider, M.D.
Independent Director
Independent Director
1.39K
-23.24%
Mr. Michel Lagarde
Mr. Michel Lagarde
Independent Director
Independent Director
1.13K
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Reshma Kewalramani, M.D.
Dr. Reshma Kewalramani, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
47.80K
+28.61%
Mr. Bruce I. Sachs
Mr. Bruce I. Sachs
Lead Independent Director
Lead Independent Director
39.00K
-15.38%
Dr. Ourania (Nia) Tatsis, Ph.D.
Dr. Ourania (Nia) Tatsis, Ph.D.
Executive Vice President, Chief Regulatory and Quality Officer
Executive Vice President, Chief Regulatory and Quality Officer
36.25K
+18.62%
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
35.24K
--
Ms. Joy Liu
Ms. Joy Liu
Corporate Secretary
Corporate Secretary
19.07K
-4.34%
Mr. Jonathan Biller, J.D.
Mr. Jonathan Biller, J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
13.66K
-78.45%
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Vertex Pharmaceuticals Inc?
Die fünf größten Anteilseigner von Vertex Pharmaceuticals Inc sind: Dr. Reshma Kewalramani, M.D.
Wie viele Institutionen halten Anteile an Vertex Pharmaceuticals Inc (VRTX)?
Mit Stand vom 2026Q1 halten 3075 Institutionen Anteile an Vertex Pharmaceuticals Inc, mit einem Gesamtmarktwert von etwa 247.47M, was 97.50% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -4593876.00 gestiegen.
Was ist die größte Einnahmequelle von Vertex Pharmaceuticals Inc?
Am 2026Q1 erzielte das Geschäft mit TRIKAFTA für Vertex Pharmaceuticals Inc den höchsten Umsatz in Höhe von 2.50B, was 74.90% des Gesamtumsatzes entspricht.